相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
Ciric To et al.
CANCER DISCOVERY (2019)
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Anna Truini et al.
CLINICAL CANCER RESEARCH (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer
Smadar Laufer-Geva et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
Yoshihisa Kobayashi et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer
Rui Wan et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Capture-Based Targeted Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer
Xiaowei Mao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Driven by by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer
Emily Castellanos et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
Karen L. Reckamp et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study
Nicolas Pecuchet et al.
PLOS MEDICINE (2016)
Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Yu-Ting Wang et al.
JOURNAL OF THORACIC DISEASE (2016)
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Y. -L. Wu et al.
ANNALS OF ONCOLOGY (2015)
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma
Simona Coco et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer
Igor F. Tsigelny et al.
ONCOTARGET (2015)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non-Small-Cell Lung Cancer
Victor H. F. Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
Hiroyuki Yasuda et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
Mai He et al.
CLINICAL CANCER RESEARCH (2012)
Clinical Outcomes in Non-Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR
Kuei-Pin Chung et al.
CLINICAL CANCER RESEARCH (2012)
Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer
Jenn-Yu Wu et al.
CLINICAL CANCER RESEARCH (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
分享论文
